Andere talen Teva Pharmaceutical Industries Limited

Aandelen

TEVA

US8816242098

Beurs gesloten - Nyse Andere beurzen 22:00:02 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,01 ^USD	0,00%		-1,29%	+24,62%

17/04	Alvotech en Teva kondigen Amerikaanse FDA-goedkeuring aan van SELARSDI (ustekinumab-aekn), biosimilar voor Stelara (ustekinumab)	CI
11/04	Teva Pharmaceutical Unit zegt dat laat-fase onderzoek in China naar Ajovy om migraine te voorkomen primaire en secundaire eindpunten heeft bereikt	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22/04
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04
Teva Pharmaceutical Industries : Immediate Report	16/04
Teva Pharmaceutical Industries : Immediate Report	16/04
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	16/04
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	16/04
Teva enters into oncology biosimilar licensing agreement	16/04
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	11/04
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	11/04
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	11/04
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	09/04
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024	08/04
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	06/04
TEVA Successfully Opposed Trademark AZILIDE	05/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Teva CEO over tweede kwartaal, mogelijke schikking met DOJ

02 augustus 2023 om 21:19 uur